Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
24.03 GBX | -3.90% | +2.23% | +21.65% |
05-14 | Headlam warns of loss; EnSilica predicts revenue rise | AN |
05-08 | Hellenic Dynamics and Ondine Biomedical raise funds | AN |
Valuation
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
Capitalization 1 | 41.08 | 36.29 | 36.29 | - |
Enterprise Value (EV) 1 | 28.71 | 31.29 | 26.29 | 34.29 |
P/E ratio | -8.13 x | -6.25 x | -13.9 x | -16.7 x |
Yield | - | - | - | - |
Capitalization / Revenue | - | - | - | - |
EV / Revenue | - | - | - | - |
EV / EBITDA | -7.57 x | -7.82 x | -6.57 x | -8.57 x |
EV / FCF | -3.65 x | -1.96 x | -1.55 x | -4.9 x |
FCF Yield | -27.4% | -51.1% | -64.7% | -20.4% |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 105,334 | 145,162 | 145,162 | - |
Reference price 2 | 0.3900 | 0.2500 | 0.2500 | 0.2500 |
Announcement Date | 5/5/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
Net sales 1 | - | - | - | - |
EBITDA 1 | -3.794 | -4 | -4 | -4 |
EBIT 1 | -3.794 | -4 | -4 | -4 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) 1 | -3.801 | -5 | -4 | -4 |
Net income 1 | -3.801 | -5 | -4 | -4 |
Net margin | - | - | - | - |
EPS 2 | -0.0480 | -0.0400 | -0.0180 | -0.0150 |
Free Cash Flow 1 | -7.865 | -16 | -17 | -7 |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 5/5/23 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
Net Debt 1 | - | - | - | - |
Net Cash position 1 | 12.4 | 5 | 10 | 2 |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow 1 | -7.86 | -16 | -17 | -7 |
ROE (net income / shareholders' equity) | -36.4% | -27% | -13% | -11% |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex 1 | 4.4 | 11 | 13 | 3 |
Capex / Sales | - | - | - | - |
Announcement Date | 5/5/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+21.65% | 46.11M | |
+51.74% | 101B | |
+28.87% | 78.81B | |
-.--% | 28.21B | |
+65.40% | 11.44B | |
+17.07% | 9.66B | |
+28.64% | 9.66B | |
+6.02% | 8.04B | |
+49.12% | 7.01B | |
-39.85% | 5.67B |
- Stock Market
- Equities
- CTL Stock
- Financials CleanTech Lithium Plc